FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2619007621> ?p ?o ?g. }

• W2619007621 endingPage "80028" @default.
• W2619007621 startingPage "80020" @default.
• W2619007621 abstract "// Fan Zhang 1, * , RuiXia LingHu 1, * , XingYang Zhan 1, * , Ruisheng Li 2, * , Fan Feng 3 , Xudong Gao 4 , Lei Zhao 1, 5 and Junlan Yang 1 1 Department of Oncology, PLA General Hospital Cancer Center, Institute of Geriatric, PLA General Hospital and Beijing Key Laboratory of Cell Engineering & Antibody, Beijing, China 2 Research Center for Clinical and Translational Medicine, PLA 302 Hospital, Beijing, China 3 Department of Pharmacy, General Hospital of Shenyang Military Command, Shenyang, China 4 Department of Gastroenterology, PLA 302 Hospital, Beijing, China 5 National Clinical Research Center for Normal Aging and Geriatric & The Key Laboratory of Normal Aging and Geriatric, PLA General Hospital and Second Military Medical University, Shanghai, China * These authors have contributed equally to this work Correspondence to: Lei Zhao, email: hugoweo@163.com Junlan Yang, email: bangot34@126.com Keywords: breast cancer, adjuvant dose-dense chemotherapy, neutropenia, PEGylated-recombinant human granulocyte colony stimulating factors Received: August 20, 2016     Accepted: April 29, 2017     Published: May 24, 2017 ABSTRACT For high-risk breast cancer patients with positive axillary lymph nodes, dose-dense every-two-week epirubicin/cyclophosphamide-paclitaxel (ddEC-P) regimen is the optimal postoperative adjuvant therapy. However, this regimen is limited by the grade 3/4 neutropenia and febrile neutropenia (FN). There is an urgent need to explore the efficacy, safety and proper dosage of PEGylated granulocyte colony-stimulating factor (PEG-G-CSF) as support for ddEC-P in Chinese breast cancer patients with positive axillary lymph nodes. Prospectively, 40 women with stage IIIA to IIIC breast cancer received ddEC-P ± trastuzumab as adjuvant treatment. PEG-G-CSF was injected subcutaneously in a dose of 6 mg or 3 mg on the 2 th day of each treatment cycle. With administration of PEG-G-CSF, all of the 40 patients completed 8 cycles of ddEC-P ± trastuzumab regimen without dose reductions or treatment delays. Moreover, no FN cases were observed. Further analysis showed that the proper dosage of PEG-G-CSF was 6 mg for ddEC treatment, and 3 mg for ddP treatment. PEG-G-CSF exhibits advantages compared with G-CSF in convenient of administration and tolerance for high risk Chinese breast cancer patients. More importantly, the proper dose of PEG-G-CSF for high risk Chinese breast cancer patients during ddEC-P chemotherapy may be 6 mg for ddEC treatment and 3 mg for ddP treatment." @default.
• W2619007621 created "2017-06-05" @default.
• W2619007621 creator A5006072228 @default.
• W2619007621 creator A5032317938 @default.
• W2619007621 creator A5039096447 @default.
• W2619007621 creator A5053861321 @default.
• W2619007621 creator A5058390081 @default.
• W2619007621 creator A5065913582 @default.
• W2619007621 creator A5077142060 @default.
• W2619007621 creator A5080599894 @default.
• W2619007621 date "2017-05-24" @default.
• W2619007621 modified "2023-09-27" @default.
• W2619007621 title "Efficacy, safety and proper dose analysis of PEGylated granulocyte colony-stimulating factor as support for dose-dense adjuvant chemotherapy in node positive Chinese breast cancer patients" @default.
• W2619007621 cites W1542834205 @default.
• W2619007621 cites W1982945924 @default.
• W2619007621 cites W1984361364 @default.
• W2619007621 cites W1995429954 @default.
• W2619007621 cites W2014179352 @default.
• W2619007621 cites W2017611339 @default.
• W2619007621 cites W2023342721 @default.
• W2619007621 cites W2029759783 @default.
• W2619007621 cites W2036450045 @default.
• W2619007621 cites W2037514943 @default.
• W2619007621 cites W2084474661 @default.
• W2619007621 cites W2087926562 @default.
• W2619007621 cites W2098344328 @default.
• W2619007621 cites W2099562503 @default.
• W2619007621 cites W2101760255 @default.
• W2619007621 cites W2101979288 @default.
• W2619007621 cites W2103107752 @default.
• W2619007621 cites W2107694321 @default.
• W2619007621 cites W2114397636 @default.
• W2619007621 cites W2116780500 @default.
• W2619007621 cites W2122122462 @default.
• W2619007621 cites W2123113466 @default.
• W2619007621 cites W2127996418 @default.
• W2619007621 cites W2129812004 @default.
• W2619007621 cites W2141868250 @default.
• W2619007621 cites W2151533372 @default.
• W2619007621 cites W2154888253 @default.
• W2619007621 cites W2162585795 @default.
• W2619007621 cites W2164788594 @default.
• W2619007621 cites W2165137990 @default.
• W2619007621 cites W2336410037 @default.
• W2619007621 cites W2578993061 @default.
• W2619007621 doi "https://doi.org/10.18632/oncotarget.18145" @default.
• W2619007621 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5668117" @default.
• W2619007621 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29108384" @default.
• W2619007621 hasPublicationYear "2017" @default.
• W2619007621 type Work @default.
• W2619007621 sameAs 2619007621 @default.
• W2619007621 citedByCount "5" @default.
• W2619007621 countsByYear W26190076212018 @default.
• W2619007621 countsByYear W26190076212020 @default.
• W2619007621 countsByYear W26190076212021 @default.
• W2619007621 countsByYear W26190076212023 @default.
• W2619007621 crossrefType "journal-article" @default.
• W2619007621 hasAuthorship W2619007621A5006072228 @default.
• W2619007621 hasAuthorship W2619007621A5032317938 @default.
• W2619007621 hasAuthorship W2619007621A5039096447 @default.
• W2619007621 hasAuthorship W2619007621A5053861321 @default.
• W2619007621 hasAuthorship W2619007621A5058390081 @default.
• W2619007621 hasAuthorship W2619007621A5065913582 @default.
• W2619007621 hasAuthorship W2619007621A5077142060 @default.
• W2619007621 hasAuthorship W2619007621A5080599894 @default.
• W2619007621 hasBestOaLocation W26190076211 @default.
• W2619007621 hasConcept C121608353 @default.
• W2619007621 hasConcept C126322002 @default.
• W2619007621 hasConcept C143998085 @default.
• W2619007621 hasConcept C2776694085 @default.
• W2619007621 hasConcept C2777063308 @default.
• W2619007621 hasConcept C2777767877 @default.
• W2619007621 hasConcept C2778850193 @default.
• W2619007621 hasConcept C2780835546 @default.
• W2619007621 hasConcept C2781413609 @default.
• W2619007621 hasConcept C530470458 @default.
• W2619007621 hasConcept C71924100 @default.
• W2619007621 hasConceptScore W2619007621C121608353 @default.
• W2619007621 hasConceptScore W2619007621C126322002 @default.
• W2619007621 hasConceptScore W2619007621C143998085 @default.
• W2619007621 hasConceptScore W2619007621C2776694085 @default.
• W2619007621 hasConceptScore W2619007621C2777063308 @default.
• W2619007621 hasConceptScore W2619007621C2777767877 @default.
• W2619007621 hasConceptScore W2619007621C2778850193 @default.
• W2619007621 hasConceptScore W2619007621C2780835546 @default.
• W2619007621 hasConceptScore W2619007621C2781413609 @default.
• W2619007621 hasConceptScore W2619007621C530470458 @default.
• W2619007621 hasConceptScore W2619007621C71924100 @default.
• W2619007621 hasIssue "45" @default.
• W2619007621 hasLocation W26190076211 @default.
• W2619007621 hasLocation W26190076212 @default.
• W2619007621 hasLocation W26190076213 @default.
• W2619007621 hasLocation W26190076214 @default.
• W2619007621 hasOpenAccess W2619007621 @default.
• W2619007621 hasPrimaryLocation W26190076211 @default.
• W2619007621 hasRelatedWork W136411592 @default.
• W2619007621 hasRelatedWork W2001550640 @default.
• W2619007621 hasRelatedWork W2032853726 @default.

• next